Drug intelligence / Profile preview

YUVA-GT-F801

Development stage: Phase 1
Lead developer: Shenzhen Geno-Immune Medical Institute
Modality: Gene Therapies, Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

YUVA-GT-F801 is a gene therapy product for hemophilia A that uses lentiviral vectors to deliver a functional gene for human clotting factor VIII into patients' autologous hematopoietic stem cells and mesenchymal stem cells, which are then infused back into the patient.

Targets

F8 (Coagulation Factor VIIIa)

Beyond the preview

Go deeper on YUVA-GT-F801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YUVA-GT-F801.

Explore the full profile